Neuron23 Closes $100 Million Series C Financing Round, Nominates Clinical Candidate For Parkinson's Disease

Mar 30, 2022•over 3 years ago

Amount Raised

$100 Million

Round Type

series c

San FranciscoBiotechnology

Description

Neuron23TM Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced it has closed a $100 million Series C financing round led by SoftBank Vision Fund 2, bringing the company's total financing raised to date to $213.5 million. Neuron23's Series A and B investors – Westlake Village BioPartners, Kleiner Perkins, Redmile Group, Cowen Healthcare Investments, Acorn Bioventures, HBM Partners, Perceptive Advisors, and Surveyor Capital (a Citadel company) – also participated in the Series C financing round.

Company Information

Company

Neuron23

Location

San Francisco, California, United States

About

Neuron23™ Inc. is a leading clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The Company’s focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases.

Related People

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech